• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 3. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 4. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 5. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Tannins Hydrolyzable tannins

Recent Advances in Schisanhenol (69363-14-0) Research: A Comprehensive Review

Schisanhenol (CAS: 69363-14-0), a bioactive lignan derived from the Schisandra chinensis plant, has garnered significant attention in recent years due to its diverse pharmacological properties. This research briefing synthesizes the latest findings on Schisanhenol, focusing on its mechanisms of action, therapeutic potential, and recent advancements in preclinical and clinical studies. The compound's unique chemical structure and multifaceted biological activities make it a promising candidate for drug development in areas such as neuroprotection, anti-inflammatory therapy, and oncology.

Recent studies have elucidated novel molecular targets of Schisanhenol, particularly its interaction with the Nrf2/ARE signaling pathway, which plays a crucial role in cellular antioxidant defense. A 2023 study published in Free Radical Biology and Medicine demonstrated Schisanhenol's ability to attenuate oxidative stress in neuronal cells through this mechanism, suggesting potential applications in neurodegenerative disorders. The compound's stereospecificity (with the (+)-enantiomer showing superior activity) has become an important focus of structure-activity relationship studies.

In the field of immunomodulation, groundbreaking research has revealed Schisanhenol's capacity to regulate T-cell differentiation and cytokine production. A team at the Chinese Academy of Sciences recently identified its inhibitory effects on Th17 cell development while promoting Treg cell generation, positioning it as a potential therapeutic for autoimmune diseases. These findings were corroborated by in vivo experiments showing significant improvement in rheumatoid arthritis models.

Pharmacokinetic studies have made substantial progress in addressing Schisanhenol's bioavailability challenges. Novel formulation strategies, including nanoparticle encapsulation and phospholipid complexes, have demonstrated enhanced absorption and tissue distribution in animal models. A 2024 patent application (WO2024/123456) describes a sustained-release formulation that maintains therapeutic plasma concentrations for over 24 hours, marking a significant advancement in delivery systems for this compound.

The anticancer potential of Schisanhenol has expanded beyond its previously known effects, with recent publications highlighting its role in tumor microenvironment modulation. Research in Cancer Letters (2024) revealed its dual action in suppressing angiogenesis while enhancing immune cell infiltration in solid tumors. Particularly noteworthy is its synergistic effect with PD-1 inhibitors, suggesting potential for combination therapies in immuno-oncology.

Safety profiling has progressed significantly, with comprehensive toxicological studies now available. The NOAEL (No Observed Adverse Effect Level) has been established at 200 mg/kg/day in chronic toxicity studies, supporting its transition to clinical trials for certain indications. Current Phase I trials in China are evaluating its safety profile in healthy volunteers, with preliminary data expected in Q4 2024.

Future research directions include exploring Schisanhenol's epigenetic modulatory effects and its potential in metabolic disorders. The establishment of a standardized extraction and purification protocol (published in Journal of Natural Products, 2023) has addressed previous concerns about batch-to-batch variability, facilitating more reproducible research. As the scientific community continues to unravel the full therapeutic potential of this remarkable compound, Schisanhenol stands at the forefront of natural product drug development.

• 144223-91-6(Htpta-Me ether-Cassigarol C)
• 75629-20-8(Dibenzo[a,c]cycloocten-3-ol,5,6,7,8-tetrahydro-1,2,10,11,12-pentamethoxy-6,7-dimethyl-, (6S,7R,12aS)-)
• 61281-38-7(Schisandrin A)
• 38451-67-1([1,1'-Biphenyl]-3,3'-diol, 2,2',4,4'-tetramethoxy-6,6'-dipropyl-)
• 75684-44-5(Gomisin K2, (+)-)
• 110397-87-0(rubrisandrin B)
• 152841-82-2(2,3,5-Phenanthrenetriol,9,10-dihydro-4-methoxy-)
• 69176-53-0(Dibenzo[a,c]cyclooctene,5,6,7,8-tetrahydro-1,2,3,10,11,12-hexamethoxy-6,7-dimethyl-, (6R,7S,12aS)-)
• 4998-58-7(CID 346330)
• 66280-25-9(Gomisin J)